AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%

Q: How long will it take to read this news story?

The story "AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%" has 463 words across 18 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12%" was covered 4 days ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 126 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #22687296</li><li>URL: https://beamstart.com/news/astrazeneca-pharma-receives-nod-for-17271545126647</li></ul>

Business Standard Logo Business Standard 4d ago

AstraZeneca Pharma receives nod for cancer drug Durvalumab; stock soars 12% - Business Standard

Quick Summary:

The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.

The stock of AstraZeneca surged up to 11.90 per cent to hit an intraday high of Rs 7,549.95 per share.

Leveraging data science and artificial intelligence, AstraZeneca claims to enhance the success rates and efficiency of its research and development processes.